reviewNew England Journal of MedicineMar 16, 2011Closed access

Multiple Myeloma

APAntonio PalumboKCKenneth C. Anderson

University of Turin · Harvard University · +1 more institution

Indexed incrossref

Abstract

Autologous stem-cell transplantation and agents such as thalidomide, lenalidomide, and bortezomib have changed the management of myeloma and extended overall survival. This review discusses both the biologic features and the management of multiple myeloma.

Citation impact

2,313
total citations
FWCI
68.05
Percentile
100%
References
93
Citations per year

Authors

2

Topics & keywords

Topics
Keywords
  • Medicine
  • Lenalidomide
  • Multiple myeloma
  • Thalidomide
  • Bortezomib
  • Autologous stem-cell transplantation
  • Oncology
  • Internal medicine
No related works found for this paper.